Targeting transcription regulators

Inventiva builds on Fournier platform to tackle tough transcriptional targets

The founders of Inventiva S.A.S. are using a platform from predecessor company Laboratoires Fournier S.A. to discover small molecules that target epigenetic enzymes, transcription factors and nuclear receptors for oncology, fibrosis and autoimmune disease. The company is both building its own pipeline of compounds to out-license, and using the platform to provide discovery services.

Targeting transcription factors and nuclear receptors has proved challenging because drug candidates must penetrate cells, then disrupt a large interface between proteins.

Inventiva starts with IVALib, a library

Read the full 822 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE